Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China
GSK announced it's entered into JV with Neptunus focused on developing and manufacturing influenza vaccines for the Chinese market.
-
Large, long-term study shows Avandia has no increased overall cardiovascular risk compared to other commonly used diabetes medicines
RECORD trial also demonstrates durable blood sugar control over time with Avandia
-
World Health Organization grants Global Prequalification to GSK’s Rotarix™ vaccine
Opens access to Asia and Africa – potential to save hundreds of thousands of lives
-
Positive results with Revolade™ and Arzerra™ for difficult-to-treat blood disorders
GSK announced data for Revolade & Arzerra at EHA meeting, results show potential of improvement in QoL in two haematological conditions.
-
GSK and Concert Pharmaceuticals form alliance to develop novel deuterium-modified drugs
GSK & Concert Pharmaceuticals to collaborate on deuterium-containing medicines, incl. CTP-518, a protease inhibitor for the treatment of HIV
-
GSK’s Pazopanib significantly delayed tumor progression in patients with advanced kidney cancer
GSK announced results of a Phase III study - pazopanib reduced the risk of tumor progression or death by 54 percent compared to placebo.1
-
FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)
GSK & GEN announced that FDA voted 10:3 that ofatumumab, reasonably likely to predict clinical benefit for patients with chronic CLL.
-
US Department of Health and Human Services (HHS) purchases GSK’s A (H1N1) influenza antigen and proprietary adjuvant system
GSK announced HHS has placed initial orders for H1N1 vaccine antigen and proprietary adjuvant system, AS03.
-
GlaxoSmithKline update: A (H1N1) influenza vaccine development
GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.
-
GSK extends strategic collaboration with Aspen
GSK to acquire 16% shareholding in Aspen in exchange for transfer of specialist products and manufacturing facility in Bad Oldesloe, DE.
-
Community healthcare charities receive £300,000 from GlaxoSmithKline in recognition of their work
20 charities were formally acknowledged last night for their community-based work, as GSK awards, run in partnership with The King's Fund.
-
GlaxoSmithKline to divest US rights for Wellbutrin XL® to Biovail for $510 million
GSK in agreement to divest full commercial rights for Wellbutrin to BVF for $510 million, subject to Hart-Scott-Rodino clearance in US.
-
GlaxoSmithKline update: influenza A (H1N1)
GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.
-
Large, long-term study shows dutasteride reduced prostate cancer risk in men at increased risk of the disease
Primary endpoint achieved in REDUCE study as presented at American Urological Association
-
Emergence of a new H1N1 influenza A strain (swine influenza)
GSK is closely monitoring H1N1 strain in Mexico, US, Canada, France, Spain & New Zealand. WHO stated, situation a cause for concern.
-
GlaxoSmithKline launches alli® (orlistat 60 mg)
GSK announced, first clinically proven over the counter weight loss aid is available in pharmacies across Europe.
-
GlaxoSmithKline and Stiefel to create new world-leading specialist dermatology business
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion.
-
GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company
Creates a new focused HIV business with the sustainability to deliver significant improvements in treatment, access and shareholder value.
-
GSK submits Tyverb®/Tykerb® (lapatinib) for first-line treatment of metastatic breast cancer in Europe, US
GSK announced, submission of 2 applications to expand the use of lapatinib, therapy regimen for metastatic breast cancer.
-
Synflorix™, GlaxoSmithKline’s pneumococcal vaccine, receives European authorisation
Protection now possible against three pneumococcal strains not covered by currently available vaccine.
